Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.38 |
| ▸ | TMPRSS15 | P98073 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | CCR6 | P51684 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | KLK1 | P06870 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10587120 | 0.86 | ALDH1A1 (0.71) | ALDH1A1ABCC4MAPTSMN1; SMN2LMNA | |
| SCHEMBL16289079 | 0.80 | ALDH1A1 (0.42) | ALDH1A1ABCC4MAPTLMNAHPGD | |
| SCHEMBL12073359 | 0.78 | ALDH1A1 (0.55) | ALDH1A1ABCC4MAPTSMN1; SMN2LMNA | |
| SCHEMBL7263229 | 0.78 | ALDH1A1 (0.50) | ALDH1A1ABCC4MAPTLMNA | |
| SCHEMBL20467671 | 0.78 | MMP2 (0.40) | ALDH1A1ABCC4MAPTLMNAPOLB | |
| SCHEMBL253365 | 0.77 | ALDH1A1 (0.46) | ALDH1A1ABCC4MAPTPRSS1TMPRSS15 | |
| SCHEMBL7262524 | 0.77 | MAPT (0.59) | ALDH1A1ABCC4MAPTLMNAPOLB | |
| SCHEMBL21244095 | 0.76 | GRIK1 (0.47) | ALDH1A1PRSS1TMPRSS15 | |
| SCHEMBL21837507 | 0.76 | EPHX2 (0.41) | MAPTLMNAPOLB | |
| SCHEMBL7262031 | 0.76 | MAPT (0.62) | ALDH1A1ABCC4MAPTLMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220168383-A1 | NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2022-06-02 | — | — | US | disclosed |
| EP-3921331-A1 | NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN | Socpra Sciences Santé Et Humaines S.E.C. (CA) | 2021-12-15 | — | — | EP | disclosed |
| WO-2020160685-A1 | NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN | SOCPRA Sciences Sante et Humaines S.E.C. (CA) | 2020-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220168383-A1 | NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN | VIP, NTSR2, VIPR2 | ALDH1A1 1872/4885ABCC4 3753/4885MAPT 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.